Endocrinology

More studies are planned testing the impact of finerenone.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

The indication comes from collaborative work among experts and community leaders coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.

An analysis of cardiovascular outcomes from FIDELIO-DKD suggest finerenone use was associated with a 14% reduction in negative cardiovascular outcomes.

In a recent column Gregory Weiss, MD, uses studies from AHA Scientific Sessions 2020 to compare the cost-effectiveness of antihyperglycemic agents for reducing cardiovascular events.

The shortage of kidney donors begs a need to consider safe approaches to expand the donor pool.

An analysis of CDC data presented at AHA Scientific Sessions 2020 suggests rates of high blood pressure complications among pregnant women nearly doubled during a period lasting from 2008-2017.

Investigators used CDC HCV infographic posters to remind healthcare providers and offer educational resources about screening.

An analysis from AHA 2020 suggests an HbA1c screening protocol doubled the proportion of patients with known dysglycemia when treating patients with ST-elevation myocardial infarction.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.

Data from a pair of phase 3 trials detail the effects of sotagliflozin in patients with type 2 diabetes and other comorbidities, such as worsening heart failure and chronic kidney disease.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.

In honor of World Diabetes Day, we reached out to Lucia Novak, CRNP, to get her perspective on the role of nurses in the diabetes care model as "The Nurse and Diabetes" has been chosen as the official theme of this year's World Diabetes Day.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

A practicing endocrinologist offers her thoughts on a recent change by the AACE from the American Association of Clinical Endocrinologists to the American Association of Clinical Endocrinology.

An analysis of blood samples from more than 19k women offers greater insight into the relationship between premature menopause and cardiovascular disease risk in postmenopausal women.

Identifying early stages of chronic kidney disease in patients with sickle cell anemia has the potential of allowing for personalized treatment and better prognosis.

Analysis of data from the 5000-patient Look AHEAD Trial details the varying effects of changes in lean mass, fat mass, and waist circumference, respectively, on risk of heart failure and myocardial infarctions in patients with type 2 diabetes.